Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy

BACKGROUND: Personalised medicine and targeted therapy have revolutionised cancer treatment. However, most patients develop drug resistance and relapse after showing an initial treatment response. Two theories have been postulated; either secondary resistance mutations develop de novo during therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Heydt, Carina, Kumm, Niklas, Fassunke, Jana, Künstlinger, Helen, Ihle, Michaela Angelika, Scheel, Andreas, Schildhaus, Hans-Ulrich, Haller, Florian, Büttner, Reinhard, Odenthal, Margarete, Wardelmann, Eva, Merkelbach-Bruse, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404105/
https://www.ncbi.nlm.nih.gov/pubmed/25886408
http://dx.doi.org/10.1186/s12885-015-1311-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404105/
https://www.ncbi.nlm.nih.gov/pubmed/25886408
http://dx.doi.org/10.1186/s12885-015-1311-0

Ejemplares similares